Merck stock falls after kidney cancer drug trial fails
Investing.com Gold reports: Merck stock falls after kidney cancer drug trial fails. Full body text was unavailable at ingest time, so this brief is based on headline context.
Investing.com Gold reports: Merck stock falls after kidney cancer drug trial fails. Full body text was unavailable at ingest time, so this brief is based on headline context.